(Press-News.org) Houston - In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors (pNET), according to researchers from The University of Texas MD Anderson Cancer Center.
The findings were published in the latest New England Journal of Medicine. James C. Yao, M.D., associate professor in MD Anderson's Department of Gastrointestinal Medical Oncology, first presented the at the 2010 European Society for Medical Oncology Congress.
pNET is a more rare and less aggressive form of pancreatic cancer than the more common adenocarcinoma. Also called islet cell carcinoma, pNET involves cells that secrete a variety of hormones. Tumors can be functional and produce high amounts of hormones, or non-functional and not produce any hormones. While pNET tumors account for approximately one percent of pancreatic cancers by diagnosed incidence, they also represent 10 percent by prevalence, because of the longer survival of patients, explained Yao.
"Up until now, there have been no large-scale, well-conducted randomized studies to guide treatment decisions for patients with pancreatic neuroendocrine tumors. In fact, currently, there's only one approved therapy for the treatment of this rare disease," said Yao. "However, there's disagreement among experts treating patients with neuroendocrine tumors about how effective that therapy is, as it's highly toxic for a disease that is considered relatively indolent."
Everolimus, an immunosupressant agent used to prevent rejection of organ transplants, also has anti-angiogenic properties. It inhibits the mTOR protein, a central regulator of tumor cell division and blood vessel growth in cancer cells. The once-daily oral therapy was approved in March 2009 for advanced renal cell carcinoma, and is currently being tested in a host of other disease sites, including lymphomas, breast, skin, gastric, liver, colon and prostate cancers.
"We became interested in everolimus because we noticed a number of genetic cancer syndromes in the mTOR pathway were associated with neuroendocrine tumors, and others also found that the dysregulation of this pathway in sporadic tumors is also linked to poor prognosis. A single-center study conducted with the agent in neuroendocrine tumors at MD Anderson showed promising activity and resulted in the development of this large international trial."
In a recent manuscript published in Science, multiple mutations in the mTOR pathway were also indentified from pancreatic neuroendocrine tumors, said Yao.
The international double-blind trial, RADIANT-3, enrolled 410 patients with advanced, low or intermediate grade pNET. Patients were randomized to receive either 10 milligrams of everolimus or placebo. The primary endpoint was progression-free survival. Median exposure to everolimus was 38 weeks, compared to 16 weeks on placebo. At progression, patients were unblinded, and those randomized to placebo were offered open-label everolimus.
The researchers found that everolimus was associated with a 65 percent reduction in the risk of progression and an increase in median progression-free survival of more than six months, from 4.6 to 11 months. Eighteen-month progression-free survival was 34 percent for those in the everolimus arm, compared to 9 percent for the placebo.
"Because treatment options available to patients with pancreatic neuroendocrine tumors are so limited, and the data in terms of the size of the treatment effect is so clear, I do believe this research will have immediate clinical applications," said Yao. "Hopefully, these findings will ultimately lead to a definitive change in the standard of care for those patients with pancreatic neuroendocrine tumors."
Common side effects associated with everolimus include: an inflammation or ulceration of the mouth known as stomatis, rash, diarrhea, fatigue and infections.
At MD Anderson, a follow-up study for the treatment of pNET with everolimus and an IGFR inhibitor is soon to open, and another studying the therapy in combination with bevacizimab was just completed.
###
In addition to Yao, other authors on the international study include: Manisha H. Shah, M.D., Ohio State University Comprehensive Cancer Center; Tetsuhide Ito, M.D., Ph.D., Graduate School of Medical Sciences, Kyushu University; Catherine Lombard-Bohas, M.D., Hôpital Edouard Herriot, Hospices Civils; Edward M. Wolin, M.D., Cedars-Sinai Medical Center; Eric Van Cutsem, M.D., Ph.D., University Hospital Gasthuisberg; Timothy Hobday, M.D., Mayo Clinic; Takuji Okusaka, M.D., National Cancer Center Hospital; Jaume Capedevila, M.D., Vall d'Hebron University Hospital; Elisabeth G.E. deVries, M.D., Ph.D., University Medical Center; Paola Tomassetti, M.D., University Hospital; Marianne E. Pavel, M.D., Charite University Medicine; Kjell Oberg, M.D., Ph.D., University Hospital; and Sakina Hoosen, M.D, Thomas Haas, Ph.D., Jeremie Lincy Ph.D. and David Lebwohl, M.D., all with Novartis Oncology.
The trial was funded, in part, by Novartis. Yao serves as consultant to and receives research support from Novartis.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For seven of the past nine years, including 2010, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.
Everolimus improves progression-free survival for patients with rare pancreatic cancer
2011-02-10
ELSE PRESS RELEASES FROM THIS DATE:
Key role proposed for pediatricians in curbing tobacco use
2011-02-10
New Rochelle, NY, February 9, 2011—Nicotine addiction usually begins during the critical teenage years, and pediatric healthcare professionals can play a prominent role in promoting a tobacco-free lifestyle among children and adolescents, as described in an article published online ahead of print in Pediatric Allergy, Immunology, & Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is available free online.
Denormalization is a strategy for changing social norms and reinforcing a public perception of tobacco use as a health-compromising, ...
Nanonets give rust a boost as agent in water splitting's hydrogen harvest
2011-02-10
CHESTNUT HILL, MA (2/9/2011) – Coating a lattice of tiny wires called Nanonets with iron oxide – known more commonly as rust – creates an economical and efficient platform for the process of water splitting, an emerging clean fuel science that harvests hydrogen from water, Boston College researchers report in the online edition of the Journal of the American Chemical Society.
Assistant Professor of Chemistry Dunwei Wang and his clean energy lab pioneered the development of Nanonets in 2008 and have since shown them to be a viable new platform for a number of energy applications ...
Key to better health care may be a walk in the park
2011-02-10
The payoff for investing in public parks and recreation sites may be healthier, more physically fit residents and a less strained healthcare system, according to Penn State researchers.
Investments in parks and recreational services have a dramatic effect on health and fitness, say Geof Godbey, professor emeritus of leisure studies, and Andrew Mowen, associate professor of recreation and parks management.
"There is a strong relationship between how much money is spent to provide such services and the amount of physical activity that people take part in," said Godbey. ...
Rice University technology in human trials to spot cardiac disease, cancer, drug abuse
2011-02-10
Heart disease is a silent killer, but new microchip technology from Rice University is expected to advance the art of diagnosis.
During National Heart Health Month, Rice Professor John McDevitt will discuss the potential of this technology to detect cardiac disease early at the annual meeting of the American Association for the Advancement of Science (AAAS) in Washington, D.C., Feb. 17-21. Cardiac disease is the focus of one of six ongoing major clinical trials of Rice's programmable bio-nano-chips (PBNCs).
PBNCs combine microfluidics, nanotechnology, advanced optics ...
Revisited human-worm relationships shed light on brain evolution
2011-02-10
"Man is but a worm" was the title of a famous caricature of Darwin's ideas in Victorian England. Now, 120 years later, a molecular analysis of mysterious marine creatures unexpectedly reveals our cousins as worms, indeed.
An international team of researchers, including a neuroscientist from the University of Florida, has produced more evidence that people have a close evolutionary connection with tiny, flatworm-like organisms scientifically known as "Acoelomorphs."
The research in the Thursday (Feb. 10) issue of Nature offers insights into brain development and human ...
A race against time to find Apollo 14's lost voyagers
2011-02-10
In communities all across the US, travelers that went to the moon and back with the Apollo 14 mission are living out their quiet lives. The voyagers in question are not astronauts. They're "moon trees."
The seeds that later became moon trees orbited the moon 34 times in the Apollo 14 command module. In this classic Apollo 14 image, taken just before the lunar module landed at Fra Mauro, Earth peeks over the edge of the moon.
In communities all across the U.S., travelers that went to the moon and back with the Apollo 14 mission are living out their quiet lives. ...
Putting trees on farms fundamental to future agricultural development
2011-02-10
Nairobi, Kenya (9 February 2011) Trees growing on farms will be essential to future development. As the number of trees in forests is declining every year, the number of trees on farms is increasing. Marking the launch of the International Year of Forest by the United Nations Forum on Forests (UNFF9) in New York on 29 January, Dennis Garrity, the Director General of the World Agroforestry Centre, highlighted the importance of mixing trees with agriculture, the practice known as agroforestry.
"Over a billion hectares of agricultural land, almost half of the world's farmland, ...
New research helps explain how progesterone prevents preterm birth
2011-02-10
SAN FRANCISCO, FEB. 10, 2011 -- Research presented today at the 31st Annual meeting of the Society for Maternal-Fetal Medicine (SMFM) ― The Pregnancy Meeting™ has found that three proteins known as XIAP, BID, and Bcl-2 are responsible in part for the success of progesterone treatments in the prevention of preterm labor. They may also play an important role in triggering normal labor.
The proteins prevent preterm birth by hindering apoptosis – the normal, orderly death of cells -- in the fetal membranes. Stronger, thicker fetal membranes are less likely to rupture ...
Use of 17-hydroxyprogesterone doesn't reduce rate of preterm delivery or complications in twins
2011-02-10
SAN FRANCISCO (February 10, 2011) — In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will present findings that show that the use of the hormone 17-Hydroxyprogesterone does not reduce the rate of preterm delivery or neonatal complications in twins.
The hormone 17-Hydroxyprogesterone is sometimes used to reduce the risk of preterm labor. In 2008, the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine issued an opinion ...
Study finds that folate does not offer protection against preterm delivery
2011-02-10
SAN FRANCISCO (February 10, 2011) — In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will present findings that show that folate intake before and during pregnancy does not protect Norwegian women against spontaneous preterm delivery.
"Sufficient folate intake has been studied as a possible protecting factor against spontaneous preterm delivery with conflicting results," said Verena Senpiel, M.D., one of the study's authors. "Preterm delivery is the major cause ...